|
[1]TORRES DM, WILLIAMS CD, HARRISON SA.Features, diagnosis, and treatment of nonalcoholic fatty liver disease[J].Clin Gastroenterol Hepatol, 2012, 10 (8) :837-858.
|
|
[2]VUPPALANCHI R, CHALASANI N.Nonalcoholic fatty liver disease and non-alcoholic steatohepatitis:Sekcted practical issues in their evaluatin and management[J].Hepalology, 2009, 49 (1) :306-317.
|
|
[3]KALISH BT, LE HD, GURA KM, et al.A metabolomic analysis of two intravenous lipid emulsions in a murine model[J].PLo S One, 2013, 8 (4) :e59653.
|
|
[4]MIURA K, KODAMA Y, INOKUCHI S, et al.Toll-like receptor 9promotes steatohepatitis by induction of interleukin-1beta in mice[J].Gastroenterology, 2010, 139 (1) :323-334.
|
|
[5]WINER S, CHAN Y, PALTSER G, et al.Normalization of obesity-associated insulin resistance through immunotherapy[J].Nat Med, 2009, 15 (8) :921-929.
|
|
[6]LAURENCE A, TATO CM, DAVIDSON TS, et al.Interleukin-2signaling via STAT5 constrains T helper 17 cell generation[J].Immunity, 2007, 26 (3) :371-381.
|
|
[7]YANG XO, PANOPOULOS AD, NURIEVA R, et al.STAT3 regulates cytokine mediated generation of inflammatory helper T cells[J].J Bio Chem, 2007, 282 (13) :9358-9363.
|
|
[8]NALBANT A, ESKIER D.Genes associated with T helper 17 cell differentiation and function[J].Front Biosci (Elite Ed) , 2016, 8:427-435.
|
|
[9]ROCHA AM, SOUZA C, ROCHA GA, et al.The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia[J].Haematologica, 2011, 96 (10) :1560-1564.
|
|
[10]VONGHIA L, RUYSSERS N, SCHRIJVERS D, et al.CD4+RORγt++and Tregs in a mouse model of diet-induced nonalcoholic steatohepatitis[J].Mediators Inflamm, 2015, 2015:239623.
|
|
[11]ROLLA S, ALCHERA E, IMARISIO C, et al.The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice[J].Clin Sci (Lond) , 2016, 130 (3) :193-203.
|
|
[12]TANG Y, BIAN Z, ZHAO L, et al.Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease[J].Clin Exp Immunol, 2011, 166 (2) :281-290.
|
|
[13]ZHANG JY, ZHANG Z, LIN F, et al.Interleukin-17-producing CD4 (+) T cells increase with severity of liver damage in patients with chronic hepatitis B[J].Hepatology, 2010, 51 (1) :81-91.
|
|
[14]WRIGHT JF, BENNETT F, LI B, et al.The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex[J].J Immunol, 2008, 181 (4) :2799-2805.
|
|
[15]GAFFEN SL.An overview of IL-17 function and signaling[J].Cytokine, 2008, 43 (4) :402-407.
|
|
[16]SHEN F, GAFFEN SL.Structure-function relationships in the IL-17receptor:Implications for signal transduction and therapy[J].Cytokine, 2008, 41 (2) :92-104.
|
|
[17]MENG F, WANG K, AOYAMA T, et al.Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice[J].Gastroenterology, 2012, 143 (3) :765-776.
|
|
[18]XU R, TAO A, ZHANG S, et al.Neutralization of interleukin-17attenuates high fat diet-induced non-alcoholic fatty liver disease in mice[J].Acta Biochim Biophys Sin (Shanghai) , 2013, 45 (9) :726-733.
|
|
[19]HAREY IT, STANIEWICZ TE, GIES DA, et al.IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice[J].Hepatology, 2014, 59 (5) :1830-1839.
|
|
[20]GIES DA, MORENO-FERNANME, STTANKIEWICZ TE.Regulation of inflammation by IL-17A and IL-17F modulates non-alcoholic fatty liver disease pathogenesis[J].PLo S One, 2016, 11 (2) :e0149783.
|
|
[21]GOMES AL, TEIEIRO A, BUREN S, et al.Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma[J].Cancer Cell, 2016, 30 (1) :161-175.
|
|
[22]SABAT R, OUYANG W, WOLK K.Therapeutic opportunities of the IL-22-IL-22R1 system[J].Nat Rev Drug Discov, 2014, 13 (1) :21-38.
|
|
[23]COBEIGH MA, ROBEK MD.Protective and pathological properties of IL-22 in liver disease:Implications for viral hepatitis[J].Am J Pathol, 2013, 182 (1) :21-28.
|
|
[24]RADAEVA S, SUN R, PAN HN, et al.Interleukin 22 (IL-22) plays protective role in T cell-mediated murine hepatitis:IL-22is a survival factor for hepatocytes via STAT3 activation[J].Hepatology, 2004, 39 (5) :1332-1342.
|
|
[25]KI SH, PARK O, ZHENG M, et al.Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding:Role of signal transducer and activator of transcription[J].Hepatology, 2010, 52 (4) :1291-1300.
|
|
[26]YANG L, ZHANG Y, WANG L, et al.Amelioration of high fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22[J].J Hepatol, 2010, 53 (2) :339-347.
|
|
[27]ZHAO J, ZHANG Z, LUAN Y, et al.Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment[J].Hepatology, 2014, 59 (4) :1331-1342.
|
|
[28]LI MO, RUDENSY AY.T cell receptor signalling in the control of regulatory T cell differentiation and function[J].Nat Rev Immunol, 2016, 16 (4) :220-233.
|
|
[29]LANE N, ROBINS RA, CORNE J, et al.Regulation in chronic obstructive pulmonary disease:the role of regulatory T-cells and Th17cells[J].Clin Sci (Lond) , 2010, 119 (2) :75-86.
|
|
[30]DENNIS KL, BLANTNER NR, GOUNARI F, et al.Current status of interleukin-10 and regulatory-T cells in cancer[J].Curr Opin Oncol, 2013, 25 (6) :637-645.
|
|
[31]MA C, KESARWALA AH, EGGERT T, et al.NAFLD causes selective CD4 (+) T lymphocyte loss and promotes hepatocarcinogenesis[J].Nature, 2016, 531 (7593) :253-257.
|
|
[32]MA X, HUA J, MOHAMOOD AR, et al.A high-fat diet and regulatory T cells influence susceptibility to endotoxin-induced liver injury[J].Hepatology, 2007, 46 (5) :1519-1529.
|
|
[33]RAU M, SCHILING AK, MEERTENS J, et al.Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17/resting regulatory T cell ratio in peripheral blood and in the liver[J].J Immunol, 2016, 196 (1) :97-105.
|
|
[34]LALAZAR G, MIZRAHI M, TURGEMAN I, et al.Oral administration of OKT3 MAb to patients with NASH, promotes regulatory T-cellinduction, and alleviates insulin resistance:Results of a phase IIa blinded placebo-controlled trial[J].J Clin Immunol, 2015, 35 (4) :399-407.
|
|
[35]SAPAN HB, PATURUI I, JUSUF I, et al.Pattern of cytokine (IL-6 and IL-10) level as inflammation and antiinflammation mediator of multiple organ dysfunction syndrome (MODS) in polytrauma[J].Int J Burns Trauma, 2016, 6 (2) :37-43.
|
|
[36]HU D, WAN L, CHEN M, et al.Essential role of IL-10/STAT3in chronic stress-induced immune suppression[J].Brain Behav Immun, 2014, 36:118-127.
|
|
[37]STAPLES KJ, SMALLIE T, WILLIAMS LM, et al.IL-10 induces IL-10 in primary human monocyte-derived macrophages via the transcriptionfactor Stat 3[J].J Immunol, 2007, 178 (8) :4779-4785.
|
|
[38] CHAUDHRY A, SAMSTEIN RM, TREUTING P, et al.Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation[J].Immunity, 2011, 34 (4) :566-578.
|
|
[39]GU Y, YANG J, OUYANG X, et al.Interleukin 10 suppresses Th17 cytokines secreted by macrophages and T cells[J].Eur J Immunol, 2008, 38 (7) :1807-1813.
|
|
[40]ZHANG L, WANG XZ.Interleukin-10 and chronic liver disease[J].World J Gastroenterol, 2006, 12 (11) :1681-1685.
|
|
[41]ZAHRAN WE, SALAH EL-DIEN KA, KAMEL PG, et al.Efficacy of tumor necrosis factor and interleukin-10 analysis in the follow-up of nonalcoholic fatty liver disease progression[J].Indian J Clin Biochem, 2013, 28 (2) :141-146.
|
|
[42]PAREDES-TURRUBIARTE G, GONZAEZ-CHAVEZ A, PEREZTAMYO R, et al.Severity of non-alcoholic fatty liver disease is associated with high systemic levels of tumor necrosis factor alpha and low serum interleukin 10 in morbidly obese patients[J].Clin Exp Med, 2016, 16:193-202.
|
|
[43]VELDHOEN M, HOCING RJ, ATINS CJ, et al.TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells[J].Immunity, 2006, 24 (2) :179-189.
|
|
[44]SUN HQ, ZHANG JY, ZHANG H, et al.Increased Th17 cells contribute to disease progression in patients with HBV-associated liver cirrhosis[J].J Viral Hepat, 2012, 19 (6) :396-403.
|
|
[45]VONGHIA L, MAGRONE T, VERRIHEN A, et al.Peripheral and hepatic vein cytokine levels in correlation with non-alcoholic fatty liver disease (NAFLD) -related metabolic, histological, and haemodynamic features[J].PLo S One, 2015, 10 (11) :e0143380.
|
|
[46]MUCIDA D, HUSAIN MM, MUROI S, et al.Transcriptional reprogramming of mature CD4 helper T cells generates distinct MHC class II-restricted cytotoxic T lymphocytes[J].Nat Immunol, 2013, 14 (3) :281-289.
|
|
[47]CHAUDHRY A, RUDRA D, TREUTING P, et al.CD4+regulatory T cells control TH17 responses in a Stat3-dependent manner[J].Science, 2009, 326 (5955) :986-991.
|
|
[48]HORIGUCHI N, LAFDIL F, MILLER AM, et al.Dissociation between liver inflammation and hepatocellular damage induced by carbon tetrachloride in myeloid cell-specific signal transducer and activator of transcription 3 gene knockout mice[J].Hepatology, 2010, 51 (5) :1724-1734.
|
|
[49]CHAUDHRY A, SAMSTEIN RM, TREUTING P, et al.Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation[J].Immunity, 2011, 34 (4) :566-578.
|
DownLoad: